Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
69 active trials across 8 therapeutic areas
69
Active Trials
30
Phase 1
27
Phase 2
23
Phase 3
8
Therapeutic Areas
Portfolio Concentration: 65% of active trials in Oncology
Oncology
45 active / 98 total
Solid Tumor (Advanced)
10 active
2 Ph3
18 total since 2015
Breast Cancer
6 active
3 Ph3
9 total since 2015
Non-Hodgkin Lymphoma
4 active
1 Ph3
5 total since 2015
Myelofibrosis
3 active
8 total since 2015
NSCLC
3 active
2 Ph3
7 total since 2015
Thyroid Cancer
2 active
1 Ph3
4 total since 2015
Hepatocellular Carcinoma
2 active
2 Ph3
4 total since 2015
SCLC
2 active
1 Ph3
3 total since 2015
Hematologic Malignancies
2 active
1 Ph3
3 total since 2015
Colorectal Cancer
1 active
1 Ph3
4 total since 2015
Sarcoma
1 active
4 total since 2015
Esophageal Cancer
1 active
3 total since 2015
Lung Cancer (General)
1 active
3 total since 2015
Endometrial Cancer
1 active
1 Ph3
3 total since 2015
Pancreatic Cancer
1 active
2 total since 2015
Prostate Cancer
1 active
2 total since 2015
CLL
1 active
2 total since 2015
AML
1 active
1 total since 2015
MDS
1 active
1 total since 2015
Melanoma
1 active
1 total since 2015
Ovarian Cancer
0 active
2 total since 2015
Cervical Cancer
0 active
2 total since 2015
Neuroendocrine Tumors
0 active
2 total since 2015
Gastric Cancer
0 active
2 total since 2015
Renal Cell Carcinoma
0 active
1 total since 2015
Glioblastoma
0 active
1 total since 2015
CML
0 active
1 total since 2015
Respiratory
6 active / 14 total
Immunology
4 active / 13 total
Infectious Disease
4 active / 8 total
Cardiovascular
4 active / 4 total
Urology
2 active / 2 total
Rare Disease
2 active / 2 total
Click an indication to see competitive landscape (all sponsors in that indication).
Data: ClinicalTrials.gov (2015+)